Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Imai, Kenjiro ^a   Tsujimoto, Tetsuro ^a   Goto, Atsushi ^a   Goto, Maki ^a   Kishimoto, Miyako ^a   Yamamoto Honda, Ritsuko ^a   Noto, Hiroshi ^a   Kajio, Hiroshi ^a   Noda, Mitsuhiko ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Exenatide; Glucagon like peptide 1 agonist; Glycemic control; Liraglutide; Predictors of response; Preprandial blood glucose level

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; DIET THERAPY; DISEASE DURATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY;

EID: 84989172956     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-110     Document Type: Article

References (23)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: A patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
2. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL: Effects of glucagonlike peptide-1 receptor agonists on weight loss: systematic review and meta-Analyses of randomised controlled trials. BMJ 2012, 344:d7771.
3. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359:824-830.
4. Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, Nagai R: Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J 2013, 54:93-97.
5. Takehiro Kawata AK, Kubota A, Maeda H, Amamiya H, Takai M, Kaneshige H, Minagawa F, Iemitsu K, Kaneshiro M, Ishikawa M, Takeda H, Takuma T, Mokubo A, Machimura H, Obana M, Miyakawa M, Naka Y, Suzuki D, Terauchi Y, Toyoda M, Tanaka Y, Matsuba I: Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients? J Clin Med Res 2014, 6:138-144.
6. Kishimoto M, Noda M: Effects of exenatide in a morbidly obese patient with type 2 diabetes. Diabetes Ther 2014, 5:323-332.
7. Nambu T, Matsuda Y, Matsuo K, Kanai Y, Yonemitsu S, Muro S, Oki S: Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin. J Diabetes Investig 2012, 4:69-77.
8. Kozawa J, Inoue K, Iwamoto R, Kurashiki Y, Okauchi Y, Kashine S, Kitamura T, Maeda N, Okita K, Iwahashi H, Funahashi T, Imagawa A, Shimomura I: Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig 2012, 3:294-297.
9. Kondo Y, Satoh S, Nagakura J, Kimura M, Nezu U, Terauchi Y: Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 2013, 4:571-575.
10. Takabe M, Matsuda T, Hirota Y, Hashimoto N, Nakamura T, Sakaguchi K, Ogawa W, Seino S: C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract 2012, 98:e32-e35.
11. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA: Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the LifeLink database. Diabetes Care 2011, 34:90-95.
12. Rosenstock J, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR, Kwan AY, MacConell LA, Hoogwerf BJ: Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012, 35:955-958.
13. Yoon HJ, Cho YZ, Kim JY, Kim BJ, Park KY, Koh GP, Lee DH, Lim DM: Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients. Diabetes Metab J 2012, 36:379-387.
14. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Hiroshi I, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program valu. J Diabetes Investig 2012, 3:39-40.
15. He L: Insulin secretagogues: old and new. Diabetes Rev 1999, 7:139-153.
16. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
17. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-Treatment trial. Lancet 2009, 373:473-481.
18. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR: Long-Term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013, 15:204-212.
19. Monnier L, Colette C, Rabasa-Lhoret R, Lapinski H, Caubel C, Avignon A, Boniface H: Morning hyperglycemic excursions: A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002, 25:737-741.
20. Monnier L, Colette C, Dunseath GJ, Owens DR: The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007, 30:263-269.
21. Yamamoto-Honda RKH, Hashimoto S, Takahashi Y, Yoshida Y, Hasegawa C, Akanuma Y, Noda M: Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J 2008, 55:913-923.
22. Ceriello A, Colagiuri S: International Diabetes Federation guideline for management of postmeal glucose: A review of recommendations. Diabet Med 2008, 25:1151-1156.
23. Klonoff DC: Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005, 28:1231-1239.